Catalent Inc (CTLT) |
|
109.38 0.12 (0.11%)
|
04-13 08:24 |
|
Open: |
108.5 |
Pre. Close: |
109.26 |
|
High:
|
109.795 |
Low:
|
107.9925 |
|
Volume:
|
1,014,916 |
Market Cap:
|
18,619M |
|
|
|
|
Catalent, Inc., together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral vector gene therapy; formulation, development, and manufacturing for parenteral dose forms, including prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. It has a collaboration with the Janssen Pharmaceutical Companies; Arcturus Therapeutics Holdings Inc.; and BrainStorm Cell Therapeutics Inc. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
109.922 - 110.344 |
110.344 - 110.767 |
|
Low:
|
106.867 - 107.38 |
107.38 - 107.893 |
|
Close:
|
108.556 - 109.338 |
109.338 - 110.121 |
|
Technical analysis |
as of: 2021-04-12 4:51:38 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 130.87 One year: 152.85 |
| Support: |
Support1: 104.65  Support2: 100.08 |
| Resistance: |
Resistance1: 112.04 Resistance2: 130.87 |
| Pivot: |
105.88 |
| Moving Average: |
MA(5): 107.85 MA(20): 105.73
MA(100): 107.46 MA(250): 91.89 |
| MACD: |
MACD(12,26): -0.24 Signal(9): -1.09 |
| Stochastic oscillator: |
%K(14,3): 71.93 %D(3): 63.88 |
| RSI: |
RSI(14): 55.23 |
| 52-week: |
High: 127.68 Low: 54.21 Change(%): 93.0 |
| Average Vol(K): |
3-Month: 105688 10-Days: 76876 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.CTLT has closed below upper band by 15.1%. Bollinger Bands are 33.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Mon, 12 Apr 2021
Is CTLT Stock A Buy or Sell? - Yahoo Finance
Fri, 09 Apr 2021
Catalent Inc (CTLT) gains 1.71% for April 09 - Equities.com
Thu, 08 Apr 2021
Catalent Inc (CTLT) gains 1.19% for April 08 - Equities.com
Wed, 07 Apr 2021
Catalent Inc (CTLT) falls 0.81% for April 07 - Equities.com
Wed, 07 Apr 2021
Catalent (CTLT) Expands Deal With Moderna for COVID-19 Vaccine - Yahoo Finance
Wed, 07 Apr 2021
Catalent Inc (CTLT) gains 1.21% for April 06 - Equities.com
|
Financial Analysis |
| Growth |
|
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Outperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers General Specialty & Generic |
| Shares Out. (M) |
170 |
| Shares Float (M) |
169 |
|
% Held by Insiders
|
0.56 |
|
% Held by Institutions
|
101.73 |
|
Shares Short (K)
|
2,340 |
|
Shares Short P. Month (K)
|
2,040 |
Stock Financials |
|
EPS
|
1.800 |
|
EPS Est This Year
|
1.630 |
|
EPS Est Next Year
|
1.820 |
|
Book Value (p.s.)
|
20.310 |
|
Profit Margin
|
9.98 |
|
Operating Margin
|
14.88 |
|
Return on Assets (ttm)
|
4.5 |
|
Return on Equity (ttm)
|
11.3 |
|
Qtrly Rev. Growth
|
26.3 |
|
Gross Profit (p.s.)
|
5.776 |
|
Sales Per Share
|
20.325 |
|
EBITDA (p.s.)
|
4.623 |
|
Qtrly Earnings Growth
|
94.30 |
|
Operating Cash Flow (M)
|
518 |
|
Levered Free Cash Flow (M)
|
-256 |
Stock Valuations |
|
PE Ratio
|
60.77 |
|
PEG Ratio
|
|
|
Price to Book value
|
5.39 |
|
Price to Sales
|
5.38 |
|
Price to Cash Flow
|
35.94 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
